KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) FCF Margin (2016 - 2025)

Pacific Biosciences Of California has reported FCF Margin over the past 16 years, most recently at 44.64% for Q4 2025.

  • Quarterly results put FCF Margin at 44.64% for Q4 2025, up 3762.0% from a year ago — trailing twelve months through Dec 2025 was 71.2% (up 6661.0% YoY), and the annual figure for FY2025 was 71.2%, up 6661.0%.
  • FCF Margin for Q4 2025 was 44.64% at Pacific Biosciences Of California, up from 48.44% in the prior quarter.
  • Over the last five years, FCF Margin for PACB hit a ceiling of 44.64% in Q4 2025 and a floor of 252.99% in Q1 2023.
  • Median FCF Margin over the past 5 years was 111.78% (2024), compared with a mean of 132.78%.
  • Biggest five-year swings in FCF Margin: tumbled -56347bps in 2021 and later skyrocketed 13725bps in 2023.
  • Pacific Biosciences Of California's FCF Margin stood at 95.92% in 2021, then crashed by -150bps to 239.35% in 2022, then soared by 57bps to 102.1% in 2023, then rose by 19bps to 82.26% in 2024, then surged by 46bps to 44.64% in 2025.
  • The last three reported values for FCF Margin were 44.64% (Q4 2025), 48.44% (Q3 2025), and 75.26% (Q2 2025) per Business Quant data.